Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Dermatologic 3

Conditions

Keratosis, Actinic 18Keratosis 3Condylomata Acuminata 3Carcinoma, Basal Cell 3Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Glioblastoma 2Warts 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Sialorrhea 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Atypical Squamous Cells of the Cervix 1Adenocarcinoma 1

Interventions

Imiquimod 3tirbanibulin 2methyl 5-aminolevulinate 1Ointments 1BF-200 ALA 13-ingenyl angelate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Keratosis × Imiquimod × Clear all
NCT00116649 2010-07-20

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

Graceway Pharmaceuticals, LLC

Phase 4 Completed
551 enrolled 11 charts
Dermatologic

Keratosis, Keratosis, Actinic

NCT00114023 2007-02-19

1-Year Follow up to the 1473-IMIQ Study

Graceway Pharmaceuticals, LLC

Completed
84 enrolled
Dermatologic

Keratosis, Keratosis, Actinic

NCT00115154 2007-02-19

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

Graceway Pharmaceuticals, LLC

Phase 4 Completed
270 enrolled
Dermatologic

Keratosis, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡